Condition: Magnetic Resonance Imaging · Hepatocellular Carcinoma · Screening · Sponsor: Naik Vietti Violi
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
This description comes directly from the study's public registry record.
Naik Vietti Violi, MD · +41213144556 · naik.vietti-violi@chuv.ch
Clarisse Dromain, MD · +41213144556 · Clarisse.dromain@chuv.ch
Always discuss trial participation with your own doctor first.
| Lausanne University Hospital | Lausanne, Canton of Vaud, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05828446